Mostrar el registro sencillo del ítem
dc.contributor.author | Bustos Palomino, Javier Arturo | |
dc.contributor.author | Arroyo Hurtado, Gianfranco | |
dc.contributor.author | Gilman, Robert Hugh | |
dc.contributor.author | Soto Becerra, Percy | |
dc.contributor.author | Gonzales, Isidro | |
dc.contributor.author | Saavedra Pastor, Herbert | |
dc.contributor.author | Pretell, E. Javier | |
dc.contributor.author | Nash, Theodore E. | |
dc.contributor.author | O'Neal, Seth E. | |
dc.contributor.author | Del Brutto, Oscar H. | |
dc.contributor.author | Gonzalez Zariquiey, Armando Emiliano | |
dc.contributor.author | García Lescano, Héctor Hugo | |
dc.contributor.author | Cysticercosis Working Group in Peru | |
dc.date.accessioned | 2020-07-14T00:00:59Z | |
dc.date.available | 2020-07-14T00:00:59Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/8245 | |
dc.description.abstract | BACKGROUND: Neurocysticercosis is a major cause of acquired epilepsy. Larval cysts in the human brain eventually resolve and either disappear or leave a calcification that is associated with seizures. In this study, we assessed the proportion of calcification in parenchymal neurocysticercosis and risk factors associated with calcification. METHODS: Data for 220 patients with parenchymal NCC from 3 trials of antiparasitic treatment were assessed to determine what proportion of the cysts that resolved 6 months after treatment ended up in a residual calcification at 1 year. Also, we evaluated the risk factors associated with calcification. RESULTS: The overall proportion of calcification was 38% (188/497 cysts, from 147 patients). Predictors for calcification at the cyst level were cysts larger than 14 mm (risk ratio [RR], 1.34; 95% confidence interval [CI], 1.02-1.75) and cysts with edema at baseline (RR, 1.39; 95% CI, 1.05-1.85). At the patient level, having had more than 24 months with seizures (RR, 1.25; 95% CI, 1.08-1.46), mild antibody response (RR, 1.14; 95% CI, 1.002-1.27), increased dose albendazole regime (RR, 1.26; 95% CI, 1.14-1.39), lower doses of dexamethasone (RR, 1.36; 95% CI, 1.02-1.81), not receiving early antiparasitic retreatment (RR, 1.45; 95% CI, 1.08-1.93), or complete cure (RR, 1.48; 95% CI, 1.29-1.71) were associated with a increased risk of calcification. CONCLUSIONS: Approximately 38% of parenchymal cysts calcify after antiparasitic treatment. Some factors associated with calcification are modifiable and may be considered to decrease or avoid calcification, potentially decreasing the risk for seizure relapses | en_US |
dc.language.iso | eng | |
dc.publisher | Oxford University Press | |
dc.relation.ispartofseries | Clinical Infectious Diseases | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | Perú | en_US |
dc.subject | Cysticercosis | en_US |
dc.subject | Taenia solium | en_US |
dc.subject | calcification | en_US |
dc.subject | risk factors | en_US |
dc.title | Frequency and determinant factors for calcification in neurocysticercosis | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1093/cid/ciaa784 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.03.08 | |
dc.relation.issn | 1537-6591 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |